Related Experiment Video
Updated: Jun 25, 2026
08:10
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
Intravitreal bevacizumab for diabetic retinopathy
J Fernando Arevalo1, Rafael A Garcia-Amaris
1Clinica Oftalmologica Centro Caracas, Caracas, Venezuela. arevalojf2020@gmail.com
Current Diabetes Reviews
|February 10, 2009
Summary
Intravitreal bevacizumab shows benefits for diabetic retinopathy (DR), including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). This treatment may improve vision and reduce macular thickness, offering a new option for patients.
Area of Science:
- Ophthalmology
- Diabetology
- Vascular Biology
Background:
- Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age population.
- Diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) are key manifestations of DR.
- Vascular endothelial growth factor (VEGF) plays a crucial role in PDR pathogenesis and macular edema.
Purpose of the Study:
- To review the benefits of intravitreal bevacizumab in managing diabetic retinopathy (DR).
- To evaluate the efficacy of intravitreal bevacizumab for diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR).
Main Methods:
- Literature review of studies investigating intravitreal bevacizumab for DR.
- Analysis of treatment outcomes, including changes in macular thickness and visual acuity (VA).
Main Results:
- Intravitreal bevacizumab demonstrated positive effects on macular thickness and VA in patients with DR.
- Benefits were observed irrespective of the specific type of macular edema present.
- Bevacizumab may offer an alternative or complementary treatment to laser photocoagulation for DME and an adjuvant therapy for PDR.
Conclusions:
- Intravitreal bevacizumab is a promising therapeutic option for diabetic retinopathy (DR), including DME and PDR.
- This treatment has the potential to improve visual outcomes and reduce macular edema.
- Bevacizumab may complement or replace existing therapies like laser photocoagulation and PRP.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...